Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: The usefulness of PSA doubling time

Japanese Journal of Clinical Oncology

Volumn 35, Issue 5, 2005, Pages 256-259

  Numata, Kousaku ^a   Azuma, Koji ^a   Hashine, Katsuyoshi ^a   Sumiyoshi, Yoshiteru ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Prostate cancer; PSA doubling time; Radical prostatectomy; Salvage radiotherapy

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION RESPONSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; ADJUVANT THERAPY; BLOOD; FORECASTING; MIDDLE AGED; PROSTATE TUMOR;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FORECASTING; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 21744432005     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi078     Document Type: Article

References (20)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-7.
2. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy: 10-year results. Urology 1999;54:884-90.
3. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zineke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
4. Stephenson AJ, Shariat SF, Zelefsky MZ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Am Med Assoc 2004;291:1325-32.
5. Catalona WJ, Smith DS. Cancer recurrence and survivalrates after anatomic radical retropubic prostatectomy for prostate cancer. J Urol 1998;160:2428-34.
6. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-6.
7. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. J Am Med Assoc 1996;276:615-9.
8. Pound CR, Partin AW, Epstein JI, Walsh, PC. Prostate specific antigen after anatomical radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;43:395-406.
9. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology 1994;43:649-59.
10. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Radical prostatectomy treated patients. J Urol 1989;141:1076-83.
11. Kakehi Y, Kamoto T, Shiraishi T, Kato T, Tobisu K, Akakura K, et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol 2002;41: 47-53.
12. D'Amico AV, Moul JW, Carrol PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-83.
13. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictor of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21: 483-9.
14. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19: 1030-9.
15. Egawa S, Ohori M, Iwamura M, Kuwao S, Baba S. Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. B J U Int 1999;84:815-20.
16. Matsui Y, Ichioka K, Terada N, Yoshimura K, Terai A, Dodo Y, et al. Impact of volume weighted mean nuclear volume on outcomes following salvage radiation therapy after radical prostatectomy. J Urol 2004;171: 687-91.
17. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-91.
18. Ornstein DK, Oh J, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998;25:591-601.
19. Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carrol P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic recurrences following radical prostatectomy. J Urol 1993;149:1024-8.
20. Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003;21: 1715-21.